|
Document Type |
: |
Article In Journal |
|
Document Title |
: |
Susceptibility and Diversity in the Therapy-Refractory Genus Scedosporium Susceptibility and Diversity in the Therapy-Refractory Genus Scedosporium |
|
Document Language |
: |
English |
|
Abstract |
: |
Scedosporium species show decreased susceptibility to the majority of systemic antifungal drugs. Acquired resistance is likely to disseminate differentially with the mode of exchange of genetic material between lineages. Inter-and intraspecific diversities of Scedosporium species were analyzed for three partitions (rDNA internal transcribed spacer gene [ITS], partial beta-tubulin gene, and amplified fragment length polymorphism profiles), with the aim to establish distribution of resistance between species, populations, and strains. Heterogeneity of and recombination between lineages were determined, and distances between clusters were calculated using a centroid approach. Clinical, geographic, and antifungal data were plotted on diversity networks. Scedosporium minutisporum, Scedosporium desertorum, and Scedosporium aurantiacum were distinguished unambiguously in all partitions and had differential antifungal susceptibility profiles (ASP). Pseudallescheria fusoidea and Pseudallescheria ellipsoidea were indistinguishable from Scedosporium boydii. Pseudallescheria angusta took an intermediate position between Scedosporium apiospermum and S. boydii. Scedosporium boydii and S. apiospermum had identical ASP. Differences in (multi)resistance were linked to individual strains. S. apiospermum and S. boydii showed limited interbreeding and were recognized as valid, sympatric species. The S. apiospermum/S. boydii group, comprising the main clinically relevant Scedosporium species, consists of separate lineages and is interpreted as a complex undergoing sympatric evolution with incomplete lineage sorting. In routine diagnostics, the lineages in S. apiospermum/S. boydii are indicated with the umbrella descriptor "S. apiospermum complex"; individual species can be identified with rDNA ITS with 96.3% confidence. Voriconazole is recommended as the first-line treatment; resistance against this compound is rare. |
|
ISSN |
: |
0066-4804 |
|
Journal Name |
: |
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY |
|
Volume |
: |
58 |
|
Issue Number |
: |
10 |
|
Publishing Year |
: |
1435 AH
2014 AD |
|
Article Type |
: |
Article |
|
Added Date |
: |
Monday, July 31, 2017 |
|
Researchers
| M Lackner | Lackner, M | Researcher | | |
| F Hagen | Hagen, F | Researcher | | |
| J Meis | Meis, J | Researcher | | |
| A van den Ende | van den Ende, A | Researcher | | |
| D Vu | Vu, D | Researcher | | |
| V Robert | Robert, V | Researcher | | |
| J Fritz | Fritz, J | Researcher | | |
| T Moussa | Moussa, T | Researcher | | |
| G de Hoog | de Hoog, G | Researcher | | |
|